McKesson (MCK)
(Delayed Data from NYSE)
$485.42 USD
+3.15 (0.65%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$485.42 USD
+3.15 (0.65%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
Thermo Fisher (TMO) Releases New Update for Omicron Detection
by Zacks Equity Research
Thermo Fisher's (TMO) TaqMan SARS-CoV-2 Mutation Panel currently offers direct identification of the novel variant of concern.
Medtronic (MDT) to Gain From Expanded Medicare Coverage for CGM
by Zacks Equity Research
CMS' expanded Medicare coverage includes continuous glucose monitors that can be integrated with Medtronic's (MDT) insulin pumps.
Exact Sciences (EXAS) Rides on Cologuard Sales Amid COVID Fear
by Zacks Equity Research
Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) better-than-expected third-quarter results and robust performances by its operating businesses.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics' (DGX) strong third-quarter performance and raised guidance.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic's (MDT) better-than-expected earnings in the fiscal second quarter and robust performance of the Diabetes arm.
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) strong third-quarter 2021 results and raised guidance.
Avanos Medical (AVNS) Set to Acquire OrthogenRx for $160M
by Zacks Equity Research
Avanos Medical's (AVNS) deal to acquire OrthogenRx is likely to boost the company's chronic pain portfolio.
Here's Why You Should Invest in West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Accuray's (ARAY) CyberKnife System Gets Shonin Approval
by Zacks Equity Research
Accuray's (ARAY) CyberKnife System can now be marketed in Japan post the Shonin approval.
Are Investors Undervaluing These Medical Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Ecolab (ECL) Stock Right Now
by Zacks Equity Research
Ecolab (ECL) continues to gain traction from a solid product portfolio and segmental strength. However, segmental weakness remains a woe.
Veeva Systems' (VEEV) Buyout to Bolster Clinical Offering
by Zacks Equity Research
Veeva Systems' (VEEV) Veracity Logic buyout can help companies to simplify complex processes and speed up clinical trials.
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
McKesson (MCK) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
McKesson (MCK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DENTSPLY SIRONA's (XRAY) New Alliance to Boost Digital Dentistry
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) and 3Shape extend their partnership to simplify digitally oriented workflows for dentists and dental technicians.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business. However, intense competition remains a woe.
Best Growth Stocks to Buy for December 13th
by Zacks Equity Research
ARCB, CSV, and MCK made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 13, 2021.
Best Value Stocks to Buy for December 13th
by Zacks Equity Research
ABG, TPH, and MCK made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 13, 2021.
NEOGEN (NEOG) Inks Deal to Boost Global Genomics Business
by Zacks Equity Research
NEOGEN's (NEOG) latest acquisition of Genetic Veterinary Sciences, Inc. will bolster the global genomics business.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of the da Vince Surgical System. Higher production costs are a woe.
OPKO Health (OPK) Receives FDA Nod for the 4Kscore Test
by Zacks Equity Research
OPKO Health (OPK) gets FDA nod for its 4Kscore Test that will further validate its value of being an important tool in the diagnosis of prostate cancer.
Are Investors Undervaluing These Medical Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
McKesson (MCK) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.